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HIV burden and correlates of infection among transfeminine persons and cisgender men who have 
sex with men in Nairobi: an observational study 
Summary 1 
Background 2 
Globally transgender persons are disproportionately affected by HIV and other sexually transmitted 3 
infections (STIs), and culturally competent prevention and treatment services are often unavailable or 4 
inaccessible. Despite recent improvements in national HIV responses for many key populations in East 5 
Africa, evidence of transgender sexual health needs to inform effective responses is sparse. We aimed 6 
to assess gender identity among men and transgender persons who have sex with men in Nairobi and 7 
explore associations with sexual health related outcomes, risk behaviour and uptake of HIV 8 
interventions  9 
Methods 10 
We recruited adult men and transgender persons who reported sex with men through respondent 11 
driven sampling during 2017 in Nairobi. We assessed gender identity, sociodemographics, sexual 12 
behaviour and HIV prevention and care uptake by self-completed survey. Participants tested for HIV, 13 
syphilis, rectal and urethral gonorrhoea and chlamydia. We compared prevalence of sexual health 14 
outcomes, risk behaviour and service uptake among transfeminine and cisgender participants using 15 
multivariable robust Poisson regression models with gender identity as the independent variable. 16 
Findings 17 
Among 618 recruits, 522 (86.1%) identified as cisgender, 70 (11.5%) transfeminine and 3 (0.7%) 18 
transmasculine. Compared to cisgender participants, transfeminine persons were more likely to be 19 
HIV positive (41.4% (28/70) v 24.6% (151/521) p=0.00087) and report rectal symptoms consistent with 20 
a current STI (16.3% (88/67) v 7.0% (38/518) p=0.014). Transfeminine persons reported higher recent 21 
male partner counts and were more likely to report recent condomless anal intercourse (62.1% 22 
(43/70) v 38.6% (208/522) p=0.00085), receptive anal intercourse (76.5% (54/70) v 45.5% (252/522) 23 
p<0.0001), transactional sex with men (57.5% (42/69) v 41.7% (240/518) p=0.023) and experience of 24 
sexual assault during the last year (23.1% (16/69) v 11.3% (65/520) p=0.019). Utilisation of pre- and 25 
post-exposure prophylaxis was low. 26 
Interpretation 27 
Transfeminine persons who have sex with men have a higher burden of HIV and associated risk 28 
behaviours compared to cisgender MSM in the same context, yet uptake of prevention and care 29 
services is poor. Policies should acknowledge the specific needs of transfeminine persons as distinct 30 
from men who have sex with men, and support providers to address these. 31 
Funding 32 
Funded by Evidence for HIV Prevention in Southern Africa (EHPSA), UK Aid 33 




The term ‘transgender’ is often used to describe those whose internal sense of their gender (their 36 
gender identity) is different from the sex they were assigned at birth1.  UNAIDS identify transgender 37 
people, in particular transgender women, as a priority population in the global response to the HIV 38 
epidemic. Yet, as of 2014, only 39% of countries reported national AIDS strategies that specifically 39 
addressed transgender persons2. Where evidence is available, transgender women are often 40 
disproportionately affected by HIV and other STIs but reviews highlight the paucity of HIV surveillance 41 
for this population generally3. Proximal origins of elevated HIV risk among transfeminine persons 42 
include high rates of receptive anal intercourse, multiple sexual partnerships and engagement in 43 
transactional sex4. Vulnerability is compounded by high rates of depression and substance use, and 44 
degrees of social exclusion and economic marginalisation that impede access to prevention and 45 
treatment options3,5. Comparable research with transgender men is limited to a few small studies 46 
predominantly in the US6. 47 
Despite a recent increase in research focussed on transgender populations, policy-informative 48 
research on the sexual health burden and needs of transgender individuals remains particularly scant 49 
in sub-Saharan Africa3,7,8. However, studies of gay, bisexual and other men who have sex with men 50 
(GBMSM) increasingly elicit gender identity measures from participants or are inclusive of 51 
transfeminine participants. A synthesis of studies between 2011-2015 in Western and Southern Africa 52 
consisting participants assigned male sex at birth and reporting recent sexual activity with men found 53 
that 26% currently identified as female or transgender9, they were almost twice as likely to be living 54 
with HIV and more often reported condomless receptive anal intercourse than cisgender GBMSM (cis-55 
MSM). Recent cohort studies with similar eligibility in South Africa10, Nigeria11 and Kenya12 also report 56 
significantly higher HIV incidence among transfeminine participants but have yet to clarify correlates 57 
of risk specific to this group. 58 
Kenya has a declining generalised HIV epidemic and an aggressive HIV prevention and control strategy 59 
that aims to be inclusive of key populations most affected by HIV13.  Yet Kenya’s most recent HIV 60 
Prevention and Treatment Strategic Plan does not include responses for transgender or other gender 61 
diverse people7,13. National evidence is limited to two small studies including transgender participants: 62 
baseline prevalence was 25% among 32 participants in the Kisumu arm of HTPN07514 whilst annual 63 
incidence of 21% was recorded among fourteen participants in a self-testing study in Malindi12. The 64 
first National Transgender Discrimination Survey also reported high levels of gender-related mental 65 
health diagnoses and suicidality, economic hardship, refusal of medical care and widespread gender-66 
related discrimination in pubic, educational, workplace and health care settings15.  In the absence of 67 
specific services for gender diverse persons, transgender and other gender diverse people seek care 68 
from key population services, specifically those catering for cis-MSM15.  69 
We sought to examine self-assessed gender identity among a population-based study of men and 70 
transgender persons who have sex with men in Nairobi, and where possible to document sexual health 71 
related outcomes, associated risk behaviour and prevention knowledge and uptake among 72 
transgender people and cis-MSM.  73 
Methods 74 
Study design and participants Between May-December 2017, respondent driven sampling (RDS) was 75 
employed to recruit 618 participants to a cross-sectional study in Nairobi. Seed participants were 76 
identified by three community organisations who provide targeted health care services to GBMSM 77 
communities in Nairobi. Following formative qualitative research, ten seeds were selected to optimise 78 
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diversity in personal characteristics (age, marital status, gender identity, socioeconomic status and 79 
location of residence within Nairobi County).  80 
After completion of study procedures, each participant received two coupons and instruction in 81 
recruiting from their social network. Inclusion criteria for recruits were: possession of a valid study 82 
coupon; age 18 or over; male gender assignment at birth or identification currently; residence within 83 
50km of Nairobi, and consensual anal or oral sexual activity with a man in the previous twelve months. 84 
Coupons detailed the location and contact details for the study site but disclosed no information about 85 
the purpose of the study or target population. To ensure legitimacy and avoid duplication, coupons 86 
were uniquely numbered, used non-standard grade watermarked paper and date stamped. The two-87 
week period of coupon validity was temporarily extended to allow coupon holders to avoid election-88 
related demonstrations near the study site in October 2017. Participants were reimbursed 300 Kenya 89 
shillings (~USD $3) for each recruit they referred to the study who subsequently participated. 90 
The study was approved by the Kenya Medical Research Institute Scientific and Ethics Review Unit 91 
(KERMI/SERU/CGMR-C/CSC 044/3334), the University of Oxford, Oxford Tropical Research Ethics 92 
Committee (OxTREC 47-16) and London School of Hygiene & Tropical Medicine Human Research Ethics 93 
Committee (REF: 14144). All participants provided separate written informed consent to the 94 
questionnaire, sample collection and sample storage, and were able to withdraw from any portion of 95 
the study. 96 
Procedures Valid coupon recipients who satisfied eligibility criteria underwent informed consent 97 
procedures. Prior participation was established using a commercially available digital fingerprint 98 
scanner. Clinic visitors who were ineligible for the study were provided details of other testing and 99 
care services. Links between participant details and study identifiers were held securely off-site. 100 
Clinical and laboratory reports were stored in secure premises and online surveys did not record 101 
identifying characteristics. 102 
Personal behaviours were collected via a tablet-administered, self-completed questionnaire in English 103 
or Kiswahili on SurveyGizmo™. Participants had access to an interviewer for clarification of questions 104 
or assisted completion. The questionnaire collected demographic characteristics; measures of sexual 105 
behaviour; alcohol and other substance use; knowledge of HIV transmission risks; awareness and use 106 
of HIV/STI prevention methods; recent anogenital STI symptoms; experiences of sexuality-related 107 
stigma, discrimination or violence; HIV testing history; measures of engagement with HIV care 108 
continuum; and pre-validated measures of alcohol use and dependence (AUDIT). Individual network 109 
degree was elicited from a sequence of questions yielding the number of Nairobi resident adult 110 
GBMSM they had met in person in the last fortnight. Participants were compensated 500 Kenya 111 
shillings (~USD $5), according with Kenyan research remuneration guidelines. 112 
Gender identity was assessed using what at the time was considered best practice via a two-step 113 
approach16, comprising assessment of sex assignment at birth (male, female or prefer not to say) and 114 
current gender identity (male, female, transgender or none of these). In line with expert 115 
recommendations5, we coded participants as ‘cisgender’ where birth assignment and currently 116 
identification was male, ‘transmasculine’ where birth assignment was female but currently 117 
identification was male or transgender, and ‘transfeminine’ where birth assignment was male sex but 118 
currently identification was female or transgender. Participants who did not currently identify as male, 119 
female or transgender could chose to specify that none of these terms applied.  120 
Participants were offered HIV counselling and rapid testing following Kenya National Guidelines using 121 
two commercial rapid HIV testing kits (Determine Alere HIV 1/2 and First Response HIV 1–2.0). Blood 122 
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specimens were tested for syphilis (TPHA/RPR) and qualitative or quantitative HIV-1 PCR conditional 123 
on rapid test results (GeneXpert® HIV-1 Qual or VL). Urine and either self- or clinical collected rectal 124 
swabs were tested for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) using PCR 125 
(GeneXpert® CT/NG).  126 
HIV positive participants not receiving care were referred to government services for initiation of 127 
antiretroviral therapy. HIV negative participants were informed of government and community clinics 128 
offering pre-exposure prophylaxis (PrEP) eligibility assessment and referred directly if requested. Free 129 
treatment for STIs and active syphilis infections was provided according to national guidelines. 130 
Condoms, lubricants, sexual health information and details of local sexual services were freely 131 
available in the study clinic. 132 
Statistical analysis RDS diagnostics including visualisation of recruitment chains, convergence and 133 
seed dependence, and statistical assessment of recruitment homophily were analysed using the rds 134 
library for R version 3.4.017. Prevalence of cisgender, transfeminine and transmasculine identities, as 135 
well as those who used none of these identity labels, were reported as crude and weighted estimates 136 
in accordance with good practice. In univariate and multivariable analyses, point estimates and 137 
prevalence ratios were sample weighted by the inverse of the individual network degree measure 138 
(RDS-II method) 18. Seeds were excluded from RDS-II analyses.  139 
Associations between gender identity and STI outcomes, sexual behaviour, sexual health knowledge 140 
and intervention access were only explored for transfeminine and cis-MSM participants, given the 141 
small sample size of other gender identities. Differences in sociodemographic characteristics of 142 
transfeminine and cis-MSM were compared using Pearson’s Х2 with second-order correction19. We 143 
used Poisson regression models with robust variance estimation (non-clustered sandwich estimator20) 144 
to estimate prevalence ratios of sexual health outcomes, behaviours and prevention and care uptake 145 
by gender identity as the independent variable. Multivariable models were confounder-adjusted for 146 
age and sociodemographic covariates in bivariate association with gender identity at p<0.200 (Wald 147 
test). Models assessing sexual behaviour associations were also adjusted for awareness of HIV status. 148 
Models of PrEP and post-exposure prophylaxis (PEP) knowledge and use were limited to participants 149 
who were HIV negative or status unaware, whilst associations with care engagement were restricted 150 
to participants living with HIV irrespective of awareness of status. Model specification and results were 151 
compared using unweighted and RDS-II weighted approaches and no marked differences were noted. 152 
Missing covariates were coded as dummy variables in models. Analyses were performed in Stata 153 
version 16. 154 
Role of the funding source The funder of the study had no role in study design, data collection, data 155 
analysis, data interpretation, or writing of the report. The corresponding author had full access to all 156 
the data in the study and had final responsibility for the decision to submit for publication. 157 
Results 158 
761 individuals presented to the study site with the intention of participation. 124 were ineligible due 159 
to fake or missing coupons (31), repeat attendance (2), intoxication (6), ineligible by other inclusion 160 
criteria (85)). Of the 637 individuals with confirmed eligibility, 29 declined participation during consent 161 
procedures (refused biometrics (2), insufficient reimbursement (5), process too long (22)). Of 608 162 
recruits and 10 seeds completing informed consent, one participant declined blood testing and six 163 
declined rectal swabs. Four seeds accounted for 516 (84.9%) recruits. Depth of recruitment ranged 164 
from 1 to 19 waves per seed (median 7) (Appendix page 1). 165 
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612 participants completed both two-step questions on sex assignment at birth and current gender 166 
identification (table 1). Six participants indicated that they preferred not to answer these questions, 167 
and were excluded. 85.3% (RDS-II 86.1%; 95%CI 82.6-88.9) identified as cisgender male. Seventy 168 
participants (11.4%; RDS-II 11.4%, 95%CI 8.8-14.7) identified as transfeminine, with approximately 169 
equal proportions currently identify as female and transgender. Only three participants identified as 170 
transmasculine. A total of 17 participants (2.8%; RDS-II 2.2%; 95%CI 1.2-3.8), the majority of whom 171 
had been assigned male sex at birth, did not self-identify as male, female or transgender.  172 
Sampling proportions of gender categories did not converge by the end of recruitment (Appendix page 173 
2). Diagnostic plots indicated a degree of seed dependence and suggested that the sampling 174 
proportion of transfeminine participants may have further increased if recruitment had continued. 175 
We found no evidence for recruitment homophily by gender identity (1.003 χ2 p=0.376).  176 
The median age of both transfeminine and cisgender participants was 24 years with no significant 177 
differences in age-distribution (table 2). The vast majority of both transfeminine and cis-MSM 178 
participants identified as gay or homosexual, and there were no significant differences in sexuality by 179 
gender identity. HIV prevalence was significantly higher among transfeminine participants (41.4%) 180 
compared to cis-MSM (24.6%, table 3). Transfeminine participants were more likely than cis-MSM to 181 
report symptoms suggestive of a rectal STI at the time of participation (16.3%) or at some point during 182 
the previous year (34.3%), and more likely to report rectal symptoms than urethral symptoms at both 183 
points. Overall prevalence of NG and CT by anatomical site did not differ significantly different by 184 
gender identity, although prevalence of rectal NG was high among transfeminine participants. The 185 
proportion of confirmed infections that were asymptomatic did not differ by site (rectal: 83.9% (73.4-186 
90.8%) urethral: 83.0% (68.6-91.6)), however symptoms were more often indicative of confirmed 187 
rectal infection when reported by transfeminine than cis-MSM participants (36.7% versus 12.5%, 188 
p=0.045) while the reverse was true of urethral symptoms (3.3% versus 18.3%, p=0.069). 189 
Transfeminine participants reported higher numbers of male partners within the last three months 190 
and were more likely to report having sold sex to men in the last year (Table 4). There were no 191 
significant differences in the reported number of transactional and non-transactional female contacts 192 
in the last year. Transfeminine participants were much more likely to report receptive anal intercourse 193 
during the last three months than cis-MSM, and twice as likely to report condomless receptive anal 194 
intercourse during that period. Conversely, transfeminine participants were significantly less likely to 195 
report insertive anal intercourse with male partners, but were no less likely to report condomless 196 
insertive anal intercourse than cis-MSM. Almost one in four transfeminine participants reported being 197 
the victim of non-consensual sex in the previous year. No associations were apparent between gender 198 
identity and alcohol or substance use. 199 
Table 5 reports measures of knowledge, access and uptake of sexual health resources, and HIV care 200 
and prevention services available in Kenya. Transfeminine participants were less likely than cis-MSM 201 
to have ever taken an HIV test and more likely to cite difficulties accessing lubricants. Among 202 
participants living with HIV, the HIV care cascade for both transfeminine and cisgender participants 203 
were significantly short of UNAIDS 90-90-90 targets (transfeminine: 72-85-71; cis-MSM: 78-86-80). 204 
Differences between transfeminine and cisgender participants were not statistically significant in this 205 
restricted sample, but were suggestive of lower status awareness and virological suppression in care 206 
among transfeminine participants. Among HIV negative and undiagnosed HIV positive participants, 207 
less than half of transfeminine participants demonstrated accurate understanding of pre- and post-208 
exposure prophylaxis, and very few reported ever using either form of biomedical prevention (PrEP 209 




This population-based study highlights the startlingly high burden of HIV and STIs among this hitherto 212 
unrecognised population within the national HIV/AIDS response in Kenya. Our findings suggest that 213 
transfeminine persons who have sex with men in Nairobi have over 80% higher prevalence of HIV than 214 
cisgender GBMSM who themselves bear a high burden of infection. Our estimates concur with those 215 
from similar populations in different African contexts over the last decade among which the pooled 216 
odds of HIV was 1.8 times that of cis-MSM in the same context9. The high prevalence of symptomatic 217 
rectal STIs among transfeminine persons, principally rectal gonorrhoea, is consistent with findings 218 
elsewhere and may both reflect high levels of sexual exposure through receptive anal intercourse as 219 
well as lack of access to prompt diagnosis or care8. The high prevalence of asymptomatic STIs is 220 
consistent with findings elsewhere in the region 11 and calls into question the adequacy of existing 221 
national syndromic management guidance for key populations21.  222 
In keeping with similar studies of transfeminine persons in other contexts5,8,9, we found higher levels 223 
of sexual risk behaviours that may in part explain the higher observed burden of HIV and rectal STIs in 224 
this population. Transfeminine persons were more likely to report condomless receptive anal 225 
intercourse, transactional sex with male partners and higher male partner counts compared to cis-226 
MSM. These findings are of particular concern juxtaposed with the extremely low usage of pre-227 
exposure and post-exposure prophylaxis in both populations, despite public provision in Kenya22, and 228 
widespread self-reports of problems accessing lubricants and condoms for transfeminine persons 229 
specifically.  230 
Occupational, housing and income instability, experience of stigma and discrimination and poor 231 
mental health also contribute to socio-ecological vulnerability to HIV acquisition among transgender 232 
populations in other settings4,23,24. Recent evidence suggests these wider issues affect the lives of 233 
transgender Kenyans too15, and our observation that 1 in 4 transfeminine people in Nairobi have been 234 
recent victims of non-consensual sex alludes to the need for urgent action to reduce the social 235 
vulnerability of this group. 236 
The behavioural exclusion criteria and network sampling methods employed likely accounts for the 237 
low representation of transmasculine persons in this study, but signals the need for further research 238 
into the full spectrum of gender diversity in Kenya and the implications for sexual health responses 25. 239 
A sizeable minority of study participants did not identify with any of the gender options presented by 240 
our two-step survey questions suggesting this common approach fails to capture the complexity of 241 
gender in this context. There is increasing recognition in other regions that such approaches may be 242 
too simplistic in not allowing individuals to affirm other specific gender identities (e.g. gender non-243 
binary, gender fluid, gender queer)16 and hence fail to capture distinct identities with specific 244 
sociodemographic and health needs26. Our observation that self-identified sexuality was not markedly 245 
different between transfeminine and cisgender participants might reflect the need for transgender 246 
persons to ‘pass’ as cis-MSM to access services15. However previous work documents the complex  247 
intersectional nature of gender role, gender expression, anal intercourse role preference and 248 
relational power dynamics among Kenyan GBMSM that challenges simplistic and common 249 
categorisation of gender or sexuality27. There is a pressing need for culturally acceptable and 250 
meaningful gender identity measures to be validated and adopted to enable providers and 251 
programmes to tailor services to meet the needs of gender diverse users. 252 
Limitations of the study include the cross-sectional design (precluding examination of causal direction 253 
of correlates) and the reliance on self-reported measures of behaviours and service uptake (subject 254 
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to memory error and social desirability bias). Furthermore, eligibility was limited to persons reporting 255 
sexual activity with men and we applied an RDS degree measure based on GBMSM network size. This 256 
reflects the primary focus of this and other such studies in the region upon GBMSM for whom 257 
advocacy, public health policy and research is well established. However gender diverse populations 258 
also comprise individuals who are not sexually active with men or do not share the same social 259 
networks28, and who therefore would not be represented in this study. Thus while our findings signal 260 
worrying patterns of sexual ill health, HIV acquisition risk and difficulties accessing resources and 261 
services among transfeminine persons who have sex with men that demand action in their own right, 262 
we caution against generalizing these findings to all transfeminine persons. Conversely, sampling 263 
within close sexual networks shared by participants may have resulted in some non-independence of 264 
observed sexually transmitted infections and may partially explain similarities seen in bacterial STI 265 
prevalence between groups. These design limitations perhaps explain why our sample failed to 266 
converge on measures of gender identity, despite satisfactory sample size and recruitment wave 267 
depth for other study measures. This underscores the need for research that is specific to gender 268 
diverse populations in Africa as distinct from GBMSM populations29. 269 
Notwithstanding these limitations, our findings have clear implications for sexual health surveillance 270 
and responses in Kenya. Our study highlights the importance of routinely distinguishing between 271 
gender identity and sexual identity in surveillance, research and service interactions with key 272 
populations, where they may otherwise be conflated29. Failure to distinguish gender diverse persons 273 
who engage with research or services designed for GBMSM not only obscures the specific needs of 274 
gender diverse service users, it also threatens to compromise our understanding of cisgender men’s 275 
burden and needs.  276 
It is crucial that Kenyan HIV/AIDS policy-makers now acknowledge and respond to the sexual health 277 
needs of transfeminine populations as distinct from GBMSM in accordance with UNAIDS/WHO 278 
guidance30. In 2015 WHO recommended essential health sector HIV interventions for transgender 279 
persons, including comprehensive condom and lubrication programming, provision of pre-exposure 280 
prophylaxis, and access to STI and community-based HIV testing, to be delivered by health-care 281 
providers sensitive to and knowledgeable of specific health needs of transgender people1. Our findings 282 
suggest these aspirations are yet to be realised for transfeminine persons in Nairobi.  283 
Developing an acceptable HIV prevention and care response for transgender persons will also require 284 
better understanding of wider priorities and needs of gender diverse Kenyans beyond sexual health. 285 
Holistic transgender-specific service models have been developed in other settings31, and limited 286 
evidence suggests that sexual health services delivered in conjunction with gender affirming services 287 
such as gender counselling and hormone therapy may improve acceptability, uptake and retention in 288 
HIV services32. Specialist services may be an unrealistic prospect outside major cities, and given half of 289 
the transfeminine persons in our study identified as women rather than transgender suggests that no 290 
single service model is likely to be universally accepted or accessible. Rather we suggest that 291 
sensitisation and gender-inclusion training across a range of service types is required, including 292 
mainstream health services and those catering to sexual minorities, as well as law enforcement 293 
agencies or other social care providers, especially in support of post-rape care1,33 294 
In summary, gender diverse persons exist in Kenya and have sexual health needs that remain largely 295 
unrecognised and unmet. Transfeminine persons who have sex with men in Nairobi have a higher 296 
burden of HIV and report greater sexual HIV acquisition risks than cis-MSM in the same context, yet 297 
uptake of available sexual health interventions is poor. National HIV/AIDS strategies should recognise 298 
this key population in the Kenyan HIV response and articulate effective and acceptable approaches to 299 
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surveillance, prevention and care. Sexual health services and programmes, particularly those targeting 300 
key populations, should routinely assess gender identity to better identify the needs of individual 301 
service users and to understand the health disparities between them. Future research must aim to 302 
understand and address obstacles to the uptake of existing sexual health programs and services for 303 
this population, and should seek to describe wider health, social and gender-affirming needs. Action 304 
to increase the cultural competence of community organisations, health and social care providers and 305 
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 Table 1: Current gender identity and gender assignment at birth, TRANSFORM participants 2017 
  
Sex assignment at birth 
 
















































 Cell content: number of participants, unweighted proportion and (in bold) RDS-II 
weighted proportion and 95% confidence interval 
Table excludes 6 persons who preferred not to answer 
 
  
Table 2: Sociodemographic characteristics of transfeminine persons and cisgender GBMSM in Nairobi, 2017 
 
  Transfeminine Cisgender GBMSM  p‡ 
  N=70 N=522   
 N n % (95% CI)
† 
 




18-23 214 22 32.3 (21.0-46.2) 192 38.6 (33.8-43.6)  
0.324 23-29 242 33 49.2 (36.0-62.4) 209 38.5 (33.8-43.5)  
30+ 136 15 22.9 (19.0-27.4) 121 22.6 (19.0-27.4 )  
Employment (current) 
Salaried 171 21 26.2 (16.3-39.5) 150 28.4 (24.1-33.2)  
0.861 
Self employed 153 14 24.1 (14.2-37.9) 139 28.3 (23.9-33.1)  
Unemployed 237 32 46.8 (33.7-60.3) 205 40.6 (35.7-45.6)  
Other 21 2 2.8 (0.5-15.2) 19 2.8 (1.6-4.8)  
Education (highest level of attendance) 
Primary 108 13 21.0 (11.9-34.5) 95 18.1 (14.6-22.2)  
0.792 Secondary 312 37 55.1 (41.5-68.0) 275 54.3 (49.2-59.2)  
Higher 165 19 23.9 (14.5-36.8) 146 27.7 (23.4-32.4)  
Income (1000s KES last month) 
<5 214 28 46.7 (33.0-60.9) 186 39.6 (34.6-44.8)  
0.162 
5 < 10 162 18 28.0 (16.9-42.7) 144 27.9 (23.5-32.7)  
10 < 20 123 15 23.9 (13.9-37.8) 108 22.0 (18.0-26.6)  
20+ 53 2 1.4 (0.3-6.1) 51 10.6 (7.7-14.2)  
Country of birth 
Kenya 465 50 75.3  (61.7-85.2) 415 79.5 (75.1-83.3)  
0.400 Other Africa 107 18 24.7 (14.8-38.3) 89 18.8 (15.1-23.2)  
Outside Africa 11 0 - - 11 1.7 (0.8-3.4)  
Self-identified sexual identity 
Gay/Homosexual 429 56 78.9 (65.1-76.6) 373 72.3 (67.6-76.6)  
0.649 Bisexual 139 11 18.5 (10.0-31.8) 128 24.6 (20.5-29.2)  
Other 15 1 2.6 (0.4-16.4) 14 3.1 (1.7-5.6)  
†: RDS-II weighted & seeds excluded ‡: Pearson χ2 with second-order survey design correction 
 
Table 3: Sexually transmitted infections and engagement with HIV care among transfeminine persons and cisgender GBMSM in Nairobi, 2017 
 
 Transfeminine 
N = 70 
Cisgender GBMSM 
n = 522 
Crude Adjusted 
 
 n/N % (95% CI)† n/N % (95% CI)† PR (95% CI) †† Wald p 
value 
aPR (95% CI) ‡ Wald p 
value 
HIV [Determine®, First Response® & Xpert® HIV-Qual]   
Positive 28/70 41.4 (29.0-55.1) 151/521 24.6 (20.7-29.0) 1.68  (1.17-2.42) 0.0050 1.83 (1.28-2.62) 0.00087 
Syphilis [TPHA/ RPR>3]         
Positive 1/70 0.8 (0.1-5.8) 4/519 1.2 (0.4-3.2) 0.71 (0.08-6.47) 0.763 0.65 (0.06- 6.61) 0.719 
Neisseria Gonorrhoea [Xpert® CTNG]   
Rectal 15/70 20.7 (11.8-33.7) 57/516 11.8 (8.8-15.5) 1.76 (0.97-3.20) 0.063 1.58 (0.84-2.97) 0.157 
Urine 3/70 3.1 (1.0-9.8) 23/519 4.6 (2.9-7.2) 0.68 (0.19-2.37) 0.540 0.66 (0.18-2.43) 0.537 
Chlamydia Trachomatis [Xpert® CTNG]    
Rectal 8/70 7.2 (3.0-16.4) 44/516 8.2 (5.9-11.4) 0.88 (0.35-2.20) 0.778 0.71 (0.32-1.56) 0.392 
Urine 5/70 5.4 (1.3-19.9) 33/519 10.9 (6.1-18.9) 0.57 (0.20-1.63) 0.296 0.57 (0.20-1.62) 0.291 
Symptoms suggestive of an STI (current)   
Rectala 8/67 16.3 (8.0-30.3) 38/518 7.0 (4.8-10.0) 2.34 (1.09-5.00) 0.029 2.57 (1.21-5.48) 0.014 
Urethralb 3/66 2.3 (0.6-8.3) 36/511 6.2 (4.2-9.0) 0.38 (0.10-1.47) 0.160 0.43 (0.11-1.69) 0.227 
Symptoms suggestive of an STI (last 12 months)   
Rectala 23/67 34.3 (22.6-48.3) 99/519 18.1 (14.6-22.3) 1.89 (1.22-2.92) 0.0041 1.96 (1.26-3.03) 0.0026 
Urethralb 13/66 16.9 (9.0-29.6) 98/512 16.7 (13.4-20.7) 1.01 (0.53-1.92) 0.978 1.04 (0.55-1.96) 0.893 
PR: prevalence ratio aPR: adjusted prevalence ratio 
†: Seeds excluded & RDS-II weighted 
††: Poisson regression with robust variance, seeds excluded & RDS-II weighting       
‡: Poisson regression with robust variance, seeds excluded, RDS-II weighting and adjusted for age, income and country of birth 
a: Participants were asked ‘Have you had any discharge from your anus or severe pain during anal sex?’ 





Table 4: Sexual and substance use behaviour among transfeminine persons and cisgender GBMSM in Nairobi, 2017 
 Transfeminine 





 n/N % (95% CI)† n/N % (95% CI)† PR (95% CI) †† Wald p 
value 
aPR (95% CI) ‡ Wald p 
value 
Sexual behaviour – male partners 
Male sexual partners (last 3 months) 
None 7/70 9.2 (3.8-20.5) 64/522 12.9 (9.9-16.8) 0.71 (0.29-1.72) 
0.020 
0.81 (0.34-1.94) 
0.042 1-3 41/70 63.6 (50.1-75.2) 346/522 73.8 (69.3-77.8) 0.86 (0.70-1.06) 0.68 (0.69-1.06) 
4 or more 22/70 27.3 (17.3-40.3) 112/522 13.3 (10.6-16.7) 2.05 (1.26-3.32) 1.93 (1.19-3.14) 
Transactional sex with male partners (last 12 months) 
Once or more 42/69 57.5 (43.7-70.2) 240/518 41.7 (36.9-46.7) 1.38 (1.06-1.79) 0.017 1.36(1.04-1.76) 0.023 
Sexual behaviour with male partners (last 3 months) 
Receptive AI 54/70 76.5 (63.2-86.0) 252/522 45.5 (40.6 – 50.5) 1.68 (1.40-2.02) <0.0001 1.55 (1.28-1.87) <0.0001 
Insertive AI 31/70 42.8 (30.3-56.3) 333/522 63.8 (58.9 – 68.5) 0.67 (0.49-0.92) 0.014 0.68 (0.49-0.93) 0.017 
Condomless anal intercourse (AI) with male partners (last 3 months) 
Any AI 43/70 62.1 (48.4-74.0) 208/522 38.6 (33.8 – 43.5) 1.61 (1.26-2.06) 0.00014 1.57 (1.22-2.01) 0.00085 
Receptive AI 34/70 48.1 (35.0-61.5) 133/522 24.4 (20.4 – 28.9) 1.97 (1.42-2.75) <0.0001 1.88 (1.34-2.65) 0.00041 
Insertive AI 18/70 26.7 (16.5-40.2) 146/522 26.5 (22.4 – 31.1) 1.01 (0.62-1.62) 0.982 0.99 (0.61-1.61) 0.975 
Sexual behaviour – female partners 
Female sexual partners (last 3 months) 
One or more 11/70 19.6 (10.8-32.9) 144/522 27.5 (23.3-32.2) 0.64 (0.36-1.15) 0.133 0.69 (0.39-1.22) 0.202 
Transactional sex with female partners (last 12 months) 
Once or more 4/70 7.7 (2.6-20.7) 52/519 9.4 (6.9-12.8) 0.82 (0.28-2.45) 0.724 0.72 (0.25-2.08) 0.543 
Condomless intercourse with female partners (last 3 months) 
Any intercourse 8/70 15.8 (7.9-29.3) 85/522 16.6 (13.3 – 20.7) 0.95  (0.47-1.92) 0.889 1.09 (0.54-2.17) 0.814 
Vaginal intercourse 7/70 13.3 (6.2-26.3) 79/522 15.4 (12.2-19.4) 0.86 (0.40-1.85) 0.706 1.01 (0.47-2.16) 0.987 
Anal intercourse 2/70 5.0 (1.3-17.8) 14/522 2.8 (1.5-5.1) 1.77 (0.41-7.73) 0.447 1.96 (0.52-7.38) 0.318 
Sexual violence 
Forced to have sex against will (last 12 months) 
Once or more 16/69 23.1 (13.7-36.3) 65/520 11.3 (8.5-14.9) 2.04 (1.16-3.58) 0.013 1.99 (1.12-3.53) 0.019 
Substance Use Behaviour         
Alcohol use  
Never 26/70 37.1 (25.2-50.9) 222/522 45.5 (40.5-50.5) 0.82 (0.56-1.18) 
0.243 
0.78 (0.55-1.13) 
0.132 Monthly 33/70 47.9 (24.9-61.3) 228/522 42.2 (37.5-47.4) 1.13 (0.83-1.53) 1.15 (0.85-1.55) 
Weekly 11/70 14.9 (7.7-27.0) 72/522 12.2 (9.3-15.8) 1.23 (0.62-2.44) 1.35 (0.68-2.67) 
Substance use  (last 3 months)a 
Once or more 11/70 13.4 (6.9-24.5) 37/522 7.3 (5.0-10.5) 1.84 (0.88-3.86) 0.105 1.77 (0.79-3.93) 0.164 
PR: prevalence ratio aPR: adjusted prevalence ratio 
†: Seeds excluded & RDS-II weighted 
††: Poisson regression with robust variance, seeds excluded & RDS-II weighting       
‡: Poisson regression with robust variance, seeds excluded, RDS-II weighting and adjusted for age, income, awareness of HIV status and country of birth 




Table 5: Access to HIV testing, prevention and care products and services 
 Transfeminine 





 n/N % (95% CI)† n/N  % (95% CI)† PR (95% CI)†† Wald p 
value 
aPR (95% CI) ‡ Wald p 
value 
Access to testing, condoms and lube [all participants] 
Ever tested for HIV  62/70 85.0 (72.0-92.6) 490/522 93.6 (90.6-95.6) 0.91 (0.80-1.03) 0.119 0.90 (0.80-1.02) 0.089 
Problems accessing condoms  36/64 55.3 (41.1-68.6) 208/510 41.9 (36.9-46.9) 1.32 (1.00-1.75) 0.053 1.30 (0.98-1.74) 0.072 
Problem accessing lubricants  43/66 67.7 (53.8-79.0) 266/509 52.1 (47.1-57.2) 1.30 (1.05–1.61) 0.017 1.31 (1.06-1.61) 0.012 
HIV care [HIV positive participants] 
Aware of status 22/28 71.9 (48.4-87.4) 122/151 78.1 (68.9-85.1) 0.92 (0.68- 1.24) 0.586 0.99 (0.74-1.32) 0.923 
Currently on ART 18/28 60.8 (39.2-78.8) 106/151 67.0 (57.2-75.5) 0.91 (0.63- 1.31) 0.603 1.00 (0.70-1.45) 0.966 
Virological suppression 13/28 42.9 (24.2-63.9) 84/151 53.8 (44.1-63.2) 0.80 (0.48-1.34) 0.394 0.94 (0.58-1.53) 0.797 
Biomedical HIV prevention knowledge and uptake [HIV negative & undiagnosed HIV positive participants] 
Pre-exposure prophylaxis 
Correct knowledgea 17/44 46.0 (30.0-62.9) 197/386 46.6 (40.9-52.4) 0.99  (0.67-1.46) 0.949 0.99 (0.67-1.45) 0.945 
Previously or currently use 2/44 3.9 (1.0-14.5) 37/394 7.0 (4.7-10.4) 0.55 (0.13-2.30) 0.414 0.58 (0.14-2.40) 0.452 
Post-exposure prophylaxis         
Correct knowledgeb 16/44 41.0 (25.5-58.6) 196/389 48.6 (42.9-54.3) 0.84 (0.55-1.30) 0.446 0.85 (0.56-1.31) 0.462 
Previously or currently use 3/45 5.0 (1.0-20.6) 30/388 6.5 (4.1-10.0) 0.78 (0.16-3.72) 0.751 0.81 (0.17-3.77) 0.786 
PR: prevalence ratio aPR: adjusted prevalence ratio 
†: Seeds excluded & RDS-II weighted 
††: Poisson regression with robust variance, seeds excluded & RDS-II weighting       
‡: Poisson regression with robust variance, seeds excluded, RDS-II weighting and adjusted for age, income and country of birth 
a: participants were asked if they knew the following information: “PrEP involves someone who does not have HIV taking a pill on an ongoing basis to prevent them from getting HIV. Most 
people who use PrEP take a pill everyday. PrEP needs to be taken before sex for it to be effective.”  
b: participants were asked if they knew the following information: “PEP is a one-month course of pills that may stop someone from becoming infected with HIV if they are exposed to the 
virus (such as by having sex without condoms. PEP needs to be started as soon as possible after an HIV risk.” 
 
Evidence before this study 
Globally, transfeminine persons bear a significantly higher burden of HIV and other sexually 
transmitted diseases. Systematic reviews highlight the lack of research attending to gender 
diversity in sub Saharan African countries with generalised HIV epidemics. We searched 
PubMed (search terms: trans*, HIV and Africa; date range 2000-2019) and found nine 
population-based studies reporting HIV risk among transfeminine persons limited to Southern 
and Western Africa among which pooled odds of HIV was 1.6 times greater than cisgender men 
who have sex with men. We found no reports of HIV risk among transmasculine persons in the 
region. 
Added value of this study 
We report HIV and STI prevalence and related sexual risk behaviours among transfeminine 
persons who have sex with men in Nairobi, the first such data from East Africa. In this setting, 
HIV prevalence was 41% among transfeminine persons and considerably higher than among 
cisgender men who have sex with men. Higher reports of concurrent rectal STIs, recent 
condomless anal intercourse and transactional sex behaviours highlight unmet needs for 
accessible sexual health promotion and services, whilst the high frequency of sexual violence 
experience suggests wider vulnerabilities of transfeminine individuals in Kenya. Our study also 
documents the existence of wider gender diversity among social networks predominated by 
African men who have sex with men. Strengths of our approach include a representative 
sampling strategy and gender inclusive eligibility criteria.   
Implications of all the available evidence 
Transfeminine individuals are an emerging key population in African generalised HIV epidemic 
settings whose sexual health needs are not specifically recognised or addressed in existing 
national key population policies and services. Existing key population service providers can 
routinely assess gender identity measures among clients, and address cultural competency of 
staff and clinics to improve acceptability to transgender clients. Holistic, integrated services 
capable of addressing sexual and mental health, harm reduction and gender affirmative needs 
are standard of care in many high-resource settings, and sustainable service models should be 
adapted. 
1 
Supplementary Figure 1: Recruitment network (Reingold Tilford algorithm), TRANSFORM 2017  
Recruitment chains start at the top of each distinct network (10 seeds) and flow downward by 
recruitment wave. 
2 
Supplementary Figure 2: Convergence and bottleneck plots by gender identity, TRANSFORM 2017  
a. Convergence plot 
b. Bottleneck plots 
The convergence plot (a) shows the cumulative RDS-II weighted estimate the proportion of different 
gender identities, by sample size attained (‘Observations’). Bottleneck plots (b) show the cumulative 
RDS-II weighted estimate for each recruitment chain (ancestors of each seed) by sample size 
attained. These are shown separately for each gender identity category and the different colours 
represent recruitment chains originating from different seed participants. 
